Clinical trial
Safety, Tolerability, Efficacy of Iguratimod in Systemic Sclerosis
NCT04515706 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety, Tolerability, Efficacy of Iguratimod in Systemic Sclerosis
- Lead sponsor
- RenJi Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- January 1, 2021
- Completion date
- January 31, 2024
- Enrollment
- 20 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
systemic sclerosis, diffuse